University of Brasilia

unb.br

Total trials

65

Active

10

Phase 3

4

Total enrollment

5,714

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Liposomal Amphotericin B2
Miltefosine 50mg1
Pentoxifylline 400mg1
Meglumine antimoniate4
Miltefosine1
Pentoxifylline1

Next readouts

  • 2024-06
  • 2025-08

Top conditions

  • Electrical Stimulation4
  • Healthy4
  • Aging3
  • Radiodermatitis3
  • Low Back Pain3
  • Chronic Pain2
  • Heart Failure2
  • Educational Technology2

Frequently asked questions about University of Brasilia

How many clinical trials does University of Brasilia have on ClinicalTrials.gov?
University of Brasilia is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Brasilia's trials are in Phase 3?
4 of University of Brasilia's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does University of Brasilia focus on?
University of Brasilia's most-studied conditions on ClinicalTrials.gov are Electrical Stimulation, Healthy, Aging, Radiodermatitis, Low Back Pain.
When are University of Brasilia's next clinical trial readouts?
University of Brasilia has 2 upcoming primary-completion readouts tracked here; the soonest is “Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly”, expected around 2024-06.